產(chǎn)品屬性：
產(chǎn)品名稱 | Rapamycin-d3 |
規(guī)格 | 500 μg、1 mg |
貨號(hào) | EY-01Y14560 |
Cas No.: 392711-19-2
別名: N/A
化學(xué)名: N/A
分子式: C51H76D3NO13
分子量: 917.2
溶解度: Chloroform: 5 mg/ml,DMSO: 25 mg/ml,Ethanol: 50 mg/ml,Methanol: 25 mg/ml
儲(chǔ)存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
Rapamycin-d3 is intended for use as an internal standard for the quantification of rapamycin by GC- or LC-MS. Rapamycin is an allosteric inhibitor of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1).1 It interacts with FKBP prolyl isomerase 1A (FKBP12) to form a complex that binds to and inhibits the kinase activity of mTORC1. Rapamycin inhibits growth of Rh1 and Rh30 rhabdomyosarcoma cells in serum-free medium, with 50% inhibition observed at concentrations of 0.1 and 0.5 ng/ml, respectively, and increases apoptosis in these cells at 100 ng/ml.2 It also induces autophagy in a variety of cell types.1 Rapamycin inhibits IL-2-induced proliferation of IL-2-dependent T cells by 50% when used at concentrations less than 5 pM.3 Formulations containing rapamycin have been used as immunosuppressive agents in the prevention of organ transplant rejection.1.Kim, Y.C., and Guan, K.-L.mTOR: A pharmacological target for autophagy regulationJ. Clin. Invest.125(1)25-32(2015)
2.Hosoi, H., Dilling, M.B., Shikata, T., et al.Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cellsCancer Res.59(4)886-894(1999)
3.Kay, J.E., Kromwel, L., Doe, S.E.A., et al.Inhibition of T and B lymphocyte proliferation by rapamycinImmunology72(4)544-549(1991)
特別提醒公司產(chǎn)品僅供科研使用
